2021.Oct.25

Application of Investigational Device Exemption for Immunohistochemistry applied to Phase II Clinical Trial of OBI-999, has been granted by FDA

1.Date of occurrence of the event:2021/10/25 2.New drug name or code: Immunohistochemistry (IHC) applied to Phase II Cohort Expansion Human Clinical Trial of OBI-999 3.Indication: Application of Investigational Device Exemption (IDE) for Immunohistochemistry (IHC) applied to Phase II cohort expansion human clinical trial of Globo H Antibody Drug conjugate, OBI-999, has been granted by FDA. […]

HOMEWhat’s NewAnnouncementsApplication of Investigational Device Exemption for Immunohistochemistry applied to Phase II Clinical Trial of OBI-999, has been granted by FDA

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2021.Oct.21

The Globo H Antibody Drug Conjugate, OBI-999, has been granted by TFDA to proceed to Phase II Human Clinical Study

2021.Oct.27

OBI-866 ”Immunogenic/Therapeutic Glycan Compositions And Uses Thereof“ Was Granted By Taiwan Intellectual Property Office